2^nd PEGS Annual Symposium on Antibodies for Cancer Therapy

References

• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 7; http://dx.doi.org/10.1038/256495a0; PMID: 1172191
   PubMed Web of Science ®Google Scholar
• Dillman RO, Shawler DL, Sobol RE, Collins HA, Beauregard JC, Wormsley SB, et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59:1036 - 45; PMID: 6896161
   PubMed Web of Science ®Google Scholar
• Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2:881 - 91; PMID: 6379121
   PubMed Web of Science ®Google Scholar
• Brown SL, Miller RA, Levy R. Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16:199 - 210; PMID: 2658083
   PubMed Web of Science ®Google Scholar
• Ritz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 1982; 59:1 - 11; PMID: 7032624
   PubMed Web of Science ®Google Scholar
• Glassy MC, Handley HH, Hagiwara H, Royston I. UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. Proc Natl Acad Sci U S A 1983; 80:6327 - 31; http://dx.doi.org/10.1073/pnas.80.20.6327; PMID: 6604917
   PubMed Web of Science ®Google Scholar
• Glassy MC, Handley HH, Surh C, Royston I. Genetically stable human hybridomas secreting tumor-reactive human monoclonal IgM. Cancer Invest 1987; 5:449 - 57; http://dx.doi.org/10.3109/07357908709032902; PMID: 3501329
   PubMed Web of Science ®Google Scholar
• Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306:517 - 22; http://dx.doi.org/10.1056/NEJM198203043060906; PMID: 6173751
   PubMed Web of Science ®Google Scholar
• Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 1997; 25:705 - 8; PMID: 9191187
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900 - 8; PMID: 10845926
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435 - 45; PMID: 7506951
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 6; http://dx.doi.org/10.1038/74704; PMID: 10742152
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48:673 - 83; http://dx.doi.org/10.1007/s002620050016; PMID: 10752475
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 52; http://dx.doi.org/10.1038/nri2747; PMID: 20414207
   PubMed Web of Science ®Google Scholar
• Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012; In press http://dx.doi.org/10.1016/j.drudis.2012.04.006; PMID: 22561895
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301 - 11; http://dx.doi.org/10.1016/j.ccr.2005.03.003; PMID: 15837620
   PubMed Web of Science ®Google Scholar
• Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008; 16:216 - 27; http://dx.doi.org/10.1016/j.str.2007.11.009; PMID: 18275813
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317 - 28; http://dx.doi.org/10.1016/S1535-6108(04)00083-2; PMID: 15093539
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al, CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109 - 19; http://dx.doi.org/10.1056/NEJMoa1113216; PMID: 22149875
   PubMed Web of Science ®Google Scholar
• Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9:482 - 501; http://dx.doi.org/10.2174/138920108786786411; PMID: 19075687
   PubMed Web of Science ®Google Scholar
• Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329 - 39; PMID: 21034674
   PubMed Web of Science ®Google Scholar
• Beck A, Senter P, Chari R. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 2011; 3:331 - 7; http://dx.doi.org/10.4161/mabs.3.4.16612; PMID: 21691144
   PubMed Web of Science ®Google Scholar
• Niculescu-Duvaz I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther 2010; 12:350 - 60; PMID: 20521224
   PubMed Web of Science ®Google Scholar
• Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011; 3:161 - 72; http://dx.doi.org/10.4161/mabs.3.2.14960; PMID: 21441786
   PubMed Web of Science ®Google Scholar
• Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30:184 - 9; http://dx.doi.org/10.1038/nbt.2108; PMID: 22267010
   PubMed Web of Science ®Google Scholar
• Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637 - 46; http://dx.doi.org/10.1021/ac3002885; PMID: 22510259
   PubMed Web of Science ®Google Scholar
• Wang C, He X, Zhou B, Li J, Li B, Qian W, et al. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. MAbs 2011; 3:67 - 75; http://dx.doi.org/10.4161/mabs.3.1.14021; PMID: 21051930
   PubMed Web of Science ®Google Scholar
• Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 2011; 128:2020 - 30; http://dx.doi.org/10.1002/ijc.25557; PMID: 20635390
   PubMed Web of Science ®Google Scholar
• Torisawa YS, Mosadegh B, Cavnar SP, Ho M, Takayama S. Transwells with Microstamped Membranes Produce Micropatterned Two-Dimensional and Three-Dimensional Co-Cultures. Tissue Eng Part C Methods 2010; 17:61 - 7; http://dx.doi.org/10.1089/ten.tec.2010.0305; PMID: 20673133
   PubMed Web of Science ®Google Scholar
• Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011; 136:473 - 8; http://dx.doi.org/10.1039/c0an00609b; PMID: 20967331
   PubMed Web of Science ®Google Scholar
• Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One 2011; 6:e14640; http://dx.doi.org/10.1371/journal.pone.0014640; PMID: 21305058
   PubMed Web of Science ®Google Scholar
• Kim H, Phung Y, Ho M. Changes in Global Gene Expression Associated with 3D Structure of Tumors: An Ex Vivo Matrix-Free Mesothelioma Spheroid Model. PLoS One 2012; 7:e39556; http://dx.doi.org/10.1371/journal.pone.0039556; PMID: 22737246
   PubMedGoogle Scholar
• Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 2011; 71:7080 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-11-2009; PMID: 21990319
   PubMed Web of Science ®Google Scholar
• Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans. J Exp Med 2009; 206:2779 - 93; http://dx.doi.org/10.1084/jem.20091107; PMID: 19858324
   PubMed Web of Science ®Google Scholar
• Vire B, David A, Wiestner A. TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. J Immunol 2011; 187:4040 - 50; http://dx.doi.org/10.4049/jimmunol.1100532; PMID: 21908732
   PubMed Web of Science ®Google Scholar
• Hofer T, Thomas JD, Burke TR Jr., Rader C. An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci U S A 2008; 105:12451 - 6; http://dx.doi.org/10.1073/pnas.0800800105; PMID: 18719095
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617 - 21; http://dx.doi.org/10.1093/protein/9.7.617; PMID: 8844834
   PubMedGoogle Scholar
• Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221 - 37; http://dx.doi.org/10.1146/annurev.med.58.070605.115320; PMID: 17059365
   PubMed Web of Science ®Google Scholar
• Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. Immunotoxins with decreased immunogenicity and improved activity. Leuk Lymphoma 2011; 52:Suppl 2 87 - 90; http://dx.doi.org/10.3109/10428194.2011.573039; PMID: 21504287
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30:1822 - 8; http://dx.doi.org/10.1200/JCO.2011.38.1756; PMID: 22355053
   PubMed Web of Science ®Google Scholar
• Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46 - 53; http://dx.doi.org/10.1016/j.ejca.2007.08.028; PMID: 17945478
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-0869; PMID: 17785569
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241 - 7; http://dx.doi.org/10.1056/NEJM200107263450402; PMID: 11474661
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23:6719 - 29; http://dx.doi.org/10.1200/JCO.2005.11.437; PMID: 16061911
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15:5274 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-0062; PMID: 19671873
   PubMed Web of Science ®Google Scholar
• Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006; 177:8822 - 34; PMID: 17142785
   PubMed Web of Science ®Google Scholar
• Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 2008; 105:11311 - 6; http://dx.doi.org/10.1073/pnas.0804851105; PMID: 18678888
   PubMed Web of Science ®Google Scholar
• Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113:3792 - 800; http://dx.doi.org/10.1182/blood-2008-08-173195; PMID: 18988862
   PubMed Web of Science ®Google Scholar
• Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 2011; 108:5742 - 7; http://dx.doi.org/10.1073/pnas.1102746108; PMID: 21436054
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989; 86:10024 - 8; http://dx.doi.org/10.1073/pnas.86.24.10024; PMID: 2513569
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3:35 - 45; http://dx.doi.org/10.1038/nrc971; PMID: 12509765
   PubMed Web of Science ®Google Scholar
• Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116:1035 - 44; http://dx.doi.org/10.1182/blood-2010-01-043737; PMID: 20439624
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709 - 20; http://dx.doi.org/10.1182/blood-2011-10-384388; PMID: 22160384
   PubMed Web of Science ®Google Scholar
• Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011; 17:1685 - 91; http://dx.doi.org/10.1038/nm.2554; PMID: 22057348
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res 2011; 44:83 - 90; http://dx.doi.org/10.1021/ar1000633; PMID: 21062101
   PubMed Web of Science ®Google Scholar
• Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009; 15:104 - 9; http://dx.doi.org/10.1038/nm.1854; PMID: 19029979
   PubMed Web of Science ®Google Scholar
• Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 2009; 69:1268 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-08-3116; PMID: 19176373
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730 - 7; http://dx.doi.org/10.1038/nm0797-730; PMID: 9212098
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5:168 - 77; http://dx.doi.org/10.1016/j.stem.2009.05.019; PMID: 19664991
   PubMed Web of Science ®Google Scholar
• Fischer M, Yen WC, Kapoun AM, Wang M, O’Young G, Lewicki J, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011; 71:1520 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-10-2817; PMID: 21193546
   PubMed Web of Science ®Google Scholar
• Gurney A, Hoey T. Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. Vasc Cell 2011; 3:18; http://dx.doi.org/10.1186/2045-824X-3-18; PMID: 21831306
   PubMedGoogle Scholar
• Mross K, Fischer R, Richly H, Scharr D, Buechert M, Stern A, et al. First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study. Molecular Cancer Therapeutics 2011; 10: Supplement 1 (Abstract A212). doi: 10.1158/1535-7163.TARG-11-A212.
   Google Scholar
• Kanakaraj P, Puffer BA, Yao X-T, Kankanala S, Boyd E, Shah RR, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012; In press
   PubMed Web of Science ®Google Scholar